Newly-merged Ardena buys Dutch bio lab
According to CEO Harry Christiaens, the acquisition – which increases Ardena’s scientists to 125 – enables the firm to provide bioanalytical services.
“With ABL’s expertise, we can now support sponsors with bioanalytical and drug discovery services to help them reach important pre-clinical and clinical milestones,” he said.
Pharmavize x Crystallics
Ardena, launched earlier this month, is the product of a merger between Belgium-based Pharmavize and Dutch firm Crystallics.
“We made the decision to combine the specialist capabilities of both Pharmavize and Crystallics last year so that we would be better placed to help our customers navigate the hurdles and pitfalls of early phase drug development.”
“Our focus is to create strong formulations and regulatory-compliant drug products for clients planning early phase clinical trials,” said Christiaens.
The Belgium-headquartered firm offers solid-state chemistry, analytical and formulation development, and early-phase clinical supply manufacturing, and has facilities in Amsterdam and Assen in the Netherlands, and Ghent, Belgium.
Christiaens said Ardena will continue to expand in line with its ‘buy and build’ strategy.
“New acquisitions will follow soon,” he said.
